The Radiodermatitis Market, estimated at USD 442.8 Mn in 2025, is expected to exhibit a CAGR of 4.3% and reach USD 594.6 Mn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
The strategies by key market players like raising awareness about innovative technologies is expected to drive the global radiodermatitis market growth over the forecast period. For instance, On January 17, 2020, 3M, U.S based healthcare company announced that the National Institute for Health, U.K. and Care Excellence (NICE) has created awareness of radiodermatitis by explaining the technology named Medtech Innovation Briefing (MIB) regarding the use of V.A.C. VERAFLO Therapy to promote wound healing in chronic and acutely infected wounds due to radiation. The system is part of 3M’s recently acquired KCI, an Acelity company, helping to improve patient outcomes by protecting and healing skin.
Global Radiodermatitis Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems regarding the transportation of drugs from one place to another.
COVID-19 had an negative impact on the global radiodermatitis market. For instance, according to an article published by National Center for Biotechnology Information ( NCBI ) explains Radiation therapy dermatitis is a side effect caused mainly by systemic therapy after previous radiation therapy. A few case reports describe radiation caloderma in breast cancer patients treated with postoperative radiotherapy after vaccination against COVID-19. In this study, researchers investigated the prevalence and severity of radiation callus dermatitis after COVID-19 vaccination in irradiated breast cancer patients.
Global Radiodermatitis Market: Key Developments
For instance, on September 15, 2020, an article published by Elsevier Inc., Netherland based published company explained of the 80 unique patients with 192 photographs, 47 patients answered the questionnaire about their symptoms during radiodermatitis. Physicians completed toxicity forms for 52 patients at the point of care. Protein count values compared to patient-reported dry and wet scale showed high specificity and negative predictive value, respectively, indicating correct identification of patients who did not report dry or wet to climb to climb the sensitivity and positive predictive value of the different measures of dry and wet scale were significantly lower. A combined measure of any scale (dry or wet) showed greater diagnostic accuracy, resulting in 72% sensitivity, 93% specificity, 75% positive predictive value and 92% negative predictive value. Photonumerical dry or wet scale ratings were significantly associated with patient reports of itching, burning or stinging, pain, and swelling.
Browse 25 Market Data Tables and 29 Figures spread through 160 Pages and in-depth TOC on Global Radiodermatitis Market, By Product Type (Topical Agents( Corticosteroids, Hydrophilic Creams, Others), Oral Medication( Corticosteroids, Other, Analgesic & Anti-Inflammatory) Dressings ( Hydrogel, Hydrocolloid, No Sting Barrier Film, Honey Impregnated Dressing, Silicone coated Dressing, Others,) By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/radiodermatitis-market-3881
Key Takeaways of the Global Radiodermatitis Market:
- Global Radiodermatitis Market is expected to exhibit a CAGR of 4.3 % during the forecast period.
- Among product type, the topical agents segment is expected to dominate the global radiodermatitis market over the forecast period, owing to the launch of a new growth medium for effective treatment techniques.
- Among region, North America is expected to be the dominant region in the global radiodermatitis market, owing to the increasing launches of treatment for the patients with radiodermatitis in the region.
- Major players operating in the global radiodermatitis market include Acelity, Inc. (3M), BMG Pharma S.r.l., ConvaTec Group PLC, DermaSciences Inc. (Integra LifeSciences Holdings Corporation), Intermed Pharmaceuticals, Mölnlycke Health Care, Smith & Nephew Plc, Stratpharma AG, Kannalife, Inc., McKesson Corporation.
Contact Us